Published in Clin Biochem Rev on May 01, 2006
Open innovation networks between academia and industry: an imperative for breakthrough therapies. Nat Med (2009) 1.50
18O labeling over a coffee break: a rapid strategy for quantitative proteomics. J Proteome Res (2008) 0.95
Bar-coded hydrogel microparticles for protein detection: synthesis, assay and scanning. Nat Protoc (2011) 0.95
High-throughput flow alignment of barcoded hydrogel microparticles. Lab Chip (2009) 0.93
Self-assembled monolayers for MALDI-TOF mass spectrometry for immunoassays of human protein antigens. Anal Chem (2007) 0.92
OMICS: Current and future perspectives in reproductive medicine and technology. J Hum Reprod Sci (2014) 0.82
Does transthyretin function as one of contributors for preeclampsia? Med Hypotheses (2010) 0.81
Pharmacogenomics and therapeutic prospects in dementia. Eur Arch Psychiatry Clin Neurosci (2008) 0.79
Identification of reduced circulating haptoglobin concentration as a biomarker of the severity of pulmonary embolism: a nontargeted proteomic study. PLoS One (2014) 0.78
High resolution two-dimensional electrophoresis of proteins. J Biol Chem (1975) 133.45
Molecular portraits of human breast tumours. Nature (2000) 94.14
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A (2001) 71.82
Gene expression profiling predicts clinical outcome of breast cancer. Nature (2002) 71.36
A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med (2002) 58.15
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 44.67
Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol Cell Proteomics (2002) 30.58
Mass spectrometry-based proteomics. Nature (2003) 28.94
Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat Biotechnol (2001) 28.01
Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat Biotechnol (1999) 21.92
Correlation between protein and mRNA abundance in yeast. Mol Cell Biol (1999) 16.95
Use of proteomic patterns in serum to identify ovarian cancer. Lancet (2002) 16.38
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol (2002) 13.81
Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell (2002) 11.83
Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol (1999) 11.78
An information-intensive approach to the molecular pharmacology of cancer. Science (1997) 11.43
A proteomic view of the Plasmodium falciparum life cycle. Nature (2002) 10.65
The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med (2000) 7.54
Establishment of Pseudomonas aeruginosa infection: lessons from a versatile opportunist. Microbes Infect (2000) 7.50
A method for the comprehensive proteomic analysis of membrane proteins. Nat Biotechnol (2003) 6.32
Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res (2004) 5.68
Analysis of the Plasmodium falciparum proteome by high-accuracy mass spectrometry. Nature (2002) 5.48
Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol (2003) 5.22
Difference gel electrophoresis: a single gel method for detecting changes in protein extracts. Electrophoresis (1997) 5.06
A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med (1998) 5.06
Current two-dimensional electrophoresis technology for proteomics. Proteomics (2004) 4.87
Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments. Bioinformatics (2004) 4.58
Autoantigen microarrays for multiplex characterization of autoantibody responses. Nat Med (2002) 4.54
Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. Blood (2003) 4.54
Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest (2006) 4.37
Imaging mass spectrometry: a new technology for the analysis of protein expression in mammalian tissues. Nat Med (2001) 4.26
Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol Cell Proteomics (2005) 4.18
Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med (2004) 4.16
Gene expression profiling of pediatric acute myelogenous leukemia. Blood (2004) 3.77
High-resolution serum proteomic features for ovarian cancer detection. Endocr Relat Cancer (2004) 3.75
Shotgun identification of protein modifications from protein complexes and lens tissue. Proc Natl Acad Sci U S A (2002) 3.70
Nuclear membrane proteins with potential disease links found by subtractive proteomics. Science (2003) 3.64
A novel experimental design for comparative two-dimensional gel analysis: two-dimensional difference gel electrophoresis incorporating a pooled internal standard. Proteomics (2003) 3.57
Disease proteomics. Nature (2003) 3.36
p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res (2000) 3.31
Protein analysis on a proteomic scale. Nature (2003) 3.12
New paths in human cancer serology. J Exp Med (1998) 3.12
Functional proteomic analysis of human nucleolus. Mol Biol Cell (2002) 3.07
Validation and development of fluorescence two-dimensional differential gel electrophoresis proteomics technology. Proteomics (2001) 3.02
Global profiling of the cell surface proteome of cancer cells uncovers an abundance of proteins with chaperone function. J Biol Chem (2002) 3.02
Proteomics and cancer: running before we can walk? Nature (2004) 2.92
Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol (2002) 2.75
From genomics to proteomics. Nature (2003) 2.70
Mass spectrometry and the age of the proteome. J Mass Spectrom (1998) 2.59
Association of mutations in a lysosomal protein with classical late-infantile neuronal ceroid lipofuscinosis. Science (1997) 2.56
Enzyme activity profiles of the secreted and membrane proteome that depict cancer cell invasiveness. Proc Natl Acad Sci U S A (2002) 2.52
Properties of 13C-substituted arginine in stable isotope labeling by amino acids in cell culture (SILAC). J Proteome Res (2003) 2.51
Candidate-based proteomics in the search for biomarkers of cardiovascular disease. J Physiol (2004) 2.42
A data review and re-assessment of ovarian cancer serum proteomic profiling. BMC Bioinformatics (2003) 2.42
Recent advancements in surface-enhanced laser desorption/ionization-time of flight-mass spectrometry. Electrophoresis (2000) 2.36
Protein microarrays: meeting analytical challenges for clinical applications. Cancer Cell (2003) 2.32
Proteomic-based prognosis of brain tumor patients using direct-tissue matrix-assisted laser desorption ionization mass spectrometry. Cancer Res (2005) 2.06
Protein microarrays: prospects and problems. Chem Biol (2001) 2.05
Protein expression profiling identifies subclasses of breast cancer and predicts prognosis. Cancer Res (2005) 2.05
Isoelectric focusing in immobilized pH gradients: principle, methodology and some applications. J Biochem Biophys Methods (1982) 1.94
Microarray gene expression profiling of B-cell chronic lymphocytic leukemia subgroups defined by genomic aberrations and VH mutation status. J Clin Oncol (2004) 1.92
Cancer Tumor antigens. Curr Opin Immunol (1997) 1.89
2D differential in-gel electrophoresis for the identification of esophageal scans cell cancer-specific protein markers. Mol Cell Proteomics (2002) 1.85
An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer. Proc Natl Acad Sci U S A (2001) 1.85
Proteome analysis of human colon cancer by two-dimensional difference gel electrophoresis and mass spectrometry. Proteomics (2004) 1.82
Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells. Nat Genet (2003) 1.79
Chemical approaches for functionally probing the proteome. Mol Cell Proteomics (2002) 1.78
Proteomic fingerprints for potential application to early diagnosis of severe acute respiratory syndrome. Clin Chem (2004) 1.76
Proteomic approaches to tumor marker discovery. Arch Pathol Lab Med (2002) 1.72
Microtubule alterations and mutations induced by desoxyepothilone B: implications for drug-target interactions. Chem Biol (2003) 1.70
Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy. J Clin Oncol (2005) 1.69
Protein arrays and microarrays. Curr Opin Chem Biol (2001) 1.65
Evaluation of two-dimensional differential gel electrophoresis for proteomic expression analysis of a model breast cancer cell system. Mol Cell Proteomics (2002) 1.60
Multiplexed sandwich assays in microarray format. J Immunol Methods (2004) 1.60
Immunoaffinity separation of plasma proteins by IgY microbeads: meeting the needs of proteomic sample preparation and analysis. Proteomics (2005) 1.58
Possible prediction of chemoradiosensitivity of esophageal cancer by serum protein profiling. Clin Cancer Res (2005) 1.54
Comprehensive proteomic analysis of breast cancer cell membranes reveals unique proteins with potential roles in clinical cancer. J Biol Chem (2002) 1.53
Counterpoint: The vision for a new diagnostic paradigm. Clin Chem (2003) 1.50
Recent developments in protein microarray technology. Angew Chem Int Ed Engl (2003) 1.43
Proteomics in early detection of cancer. Clin Chem (2001) 1.43
Signal pathway profiling of ovarian cancer from human tissue specimens using reverse-phase protein microarrays. Proteomics (2003) 1.40
Diagnostic developments involving cell-free (circulating) nucleic acids. Clin Chim Acta (2005) 1.34
Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells. Cancer Res (2001) 1.32
Albumin depletion of human plasma also removes low abundance proteins including the cytokines. Proteomics (2005) 1.31
Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer. Proteomics (2002) 1.31
Complementing genomics with proteomics: the membrane subproteome of Pseudomonas aeruginosa PAO1. Electrophoresis (2000) 1.30
Increased expression of epidermal fatty acid binding protein, cofilin, and 14-3-3-sigma (stratifin) detected by two-dimensional gel electrophoresis, mass spectrometry and microsequencing of drug-resistant human adenocarcinoma of the pancreas. Electrophoresis (1999) 1.30
Detection of cancer-specific markers amid massive mass spectral data. Proc Natl Acad Sci U S A (2003) 1.29
High-throughput proteomic analysis of human infiltrating ductal carcinoma of the breast. Proteomics (2003) 1.27
Interaction of kinesin motor domains with alpha- and beta-tubulin subunits at a tau-independent binding site. Regulation by polyglutamylation. J Biol Chem (1996) 1.24
Direct analysis of laser capture microdissected cells by MALDI mass spectrometry. J Am Soc Mass Spectrom (2002) 1.24
A distinct repertoire of autoantibodies in hepatocellular carcinoma identified by proteomic analysis. Mol Cell Proteomics (2002) 1.22
Processing of serum proteins underlies the mass spectral fingerprinting of myocardial infarction. J Proteome Res (2003) 1.22
Antigens secreted from Mycobacterium tuberculosis: identification by proteomics approach and test for diagnostic marker. Proteomics (2004) 1.20
Protein chip array profiling analysis in patients with severe acute respiratory syndrome identified serum amyloid a protein as a biomarker potentially useful in monitoring the extent of pneumonia. Clin Chem (2004) 1.18
Deciphering protein molecular signatures in cancer tissues to aid in diagnosis, prognosis, and therapy. Cancer Res (2005) 1.15
Prediction of liver fibrosis and cirrhosis in chronic hepatitis B infection by serum proteomic fingerprinting: a pilot study. Clin Chem (2004) 1.14
Polyglutamylation of tubulin as a progressive regulator of in vitro interactions between the microtubule-associated protein Tau and tubulin. Biochemistry (1994) 1.14
Identification of novel proteins associated with the development of chemoresistance in malignant melanoma using two-dimensional electrophoresis. Electrophoresis (2000) 1.14
The clinical application of proteomics. Clin Chim Acta (2005) 1.13